{"commentary":{"count":22,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":10,"youtube":9,"podcast":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02685059\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"GeparNuevo","nct_id":"NCT02685059","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=geparnuevo-nct02685059. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"GeparNuevo","arms":[{"description":"part 1: MEDI4736 (with half dose as monotherapy for the first two weeks) part 2: MEDI4736 1.5 g total for 20 weeks","label":"MEDI4736","type":"EXPERIMENTAL"},{"description":"part 1: Placebo (for the first two weeks) part 2: Placebo for 20 weeks","label":"Placebo","type":"PLACEBO_COMPARATOR"},{"description":"Nab-Paclitaxel 125 mg/m² weekly for 12 weeks","label":"Taxane","type":"ACTIVE_COMPARATOR"},{"description":"Epirubicin 90 mg/m² 2-weekly for 8 weeks","label":"Epirubicin","type":"ACTIVE_COMPARATOR"},{"description":"Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks","label":"Cyclophosphamide","type":"ACTIVE_COMPARATOR"}],"collaborators":["AstraZeneca","Celgene"],"completion_date":{"date":"2018-03","type":"ACTUAL"},"conditions":["Breast Cancer"],"enrollment":{"count":174,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"MEDI4736 (Anti PD-L1)","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"nab-Paclitaxel","type":"DRUG"},{"name":"Epirubicin","type":"DRUG"},{"name":"Cyclophosphamide","type":"DRUG"}],"last_update":"2021-02-15","lead_sponsor":"GBG Forschungs GmbH","official_title":"A Randomized Phase II Study to Investigate the Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Containing Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2018-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"pathological complete response (pCR= ypT0 ypN0)","timeFrame":"22 weeks"}],"references":[{"citation":"Loibl S, Untch M, Huober J, Schaser V, Braun M, Denkert C, Hartkopf A, Blohmer JU, Hanusch C, Link T, Reinisch M, Zahm DM, Weide R, Bjelic-Radisic V, Staib P, Tesch H, Rhiem K, Lorenz R, Rey J, Schneeweiss A. Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial. J Clin Oncol. 2026 Jun 10;44(17):1580-1586. doi: 10.1200/JCO-25-02311. Epub 2026 Apr 20.","pmid":"42008768","type":"DERIVED"},{"citation":"Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer JU, Zahm DM, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Muller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching PA, Untch M, Loibl S, Weber K, Seliger B. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. J Immunother Cancer. 2020 Nov;8(2):e001261. doi: 10.1136/jitc-2020-001261.","pmid":"33199511","type":"DERIVED"},{"citation":"Perez-Garcia J, Soberino J, Racca F, Gion M, Stradella A, Cortes J. Atezolizumab in the treatment of metastatic triple-negative breast cancer. Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25.","pmid":"32450725","type":"DERIVED"},{"citation":"Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kummel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019 Aug 1;30(8):1279-1288. doi: 10.1093/annonc/mdz158.","pmid":"31095287","type":"DERIVED"}],"start_date":{"date":"2016-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer","url":"https://clinicaltrials.gov/study/NCT02685059"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/geparnuevo-nct02685059"}